CTIF

gene product
KIAA0427
CTIF is a component of the CBP80 (NCBP1; MIM 600469)/CBP20 (NCBP2; MIM 605133) translation initiation complex that binds cotranscriptionally to the cap end of nascent mRNA. The CBP80/CBP20 complex is involved in a simultaneous editing and translation step that recognizes premature termination codons (PTCs) in mRNAs and directs PTC-containing mRNAs toward nonsense-mediated decay (NMD). On mRNAs without PTCs, the CBP80/CBP20 complex is replaced with cytoplasmic mRNA cap-binding proteins, including EIF4G (MIM 600495), and steady-state translation of the mRNAs resumes in the cytoplasm (Kim et al., 2009 [PubMed 19648179]). [supplied by OMIM, Dec 2009]
More gene data

Featured antibodies

Antibodies

 

Filters

Application

Antibodypedia Validation Initiative

Validation method

Reference

Provider

Host

Reactivity

Antibody type

Conjugate

  or   Clear
Enhanced validation
Supportive data in Antibodypedia
Data presented on provider website
Data in Antibodypedia (inconclusive)
Recommended by provider
Validated within AVI
Eligible for validation within AVI
57 antibodies from 15 providers.

Antibody properties

General

Applications

or Cancel
AntibodyRefsTypeWBELICCIPIHCFC
Novus Biologicals
4 antibodies
Atlas Antibodies
2 antibodies
antibodies-online
20 antibodies
Invitrogen Antibodies
2 antibodies
LifeSpan BioSciences, Inc.
8 antibodies
Biorbyt
5 antibodies
Aviva Systems Biology
2 antibodies
GeneTex
2 antibodies
OriGene
2 antibodies
Abnova Corporation
2 antibodies
Boster Biological Technology
1 antibody
ProSci
1 antibody
Sigma-Aldrich
3 antibodies
Creative Diagnostics
2 antibodies
United States Biological
1 antibody